分類彙整:公司新聞

聯合生物製藥為長期發展策略,董事會決議終止櫃檯買賣(問答集更新&新聞稿)

聯合生物製藥為長期發展策略,董事會決議終止櫃檯買賣(新聞稿&問答集) 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥治療氣喘和過敏單株抗體UB-221 榮獲2018臺北生技獎 新創技術銅獎

聯生藥(6471)今日表示,開發中針對治療過敏症的創新抗IgE單株抗體UB-221研發成果備受肯定,榮獲2018年台北生技獎新創技術獎之「銅獎」。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥抗IgE 抗體新藥UB-221 將進入人體臨床一期試驗

聯生藥(6471)今日表示,已向台灣食品藥物管理署提交創新抗IgE 抗體新藥UB-221 之人體臨床一期試驗申請。此臨床一期試驗主要目的在於評估UB-221 對於使用蕁麻疹一線藥物但仍無顯著效果的慢性自發性蕁麻疹(Chronic Idiopathic Urticaria,CIU) 病患上的安全性與初步療效。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥 進軍陸抗體藥市場

中國醫藥市場成長快速,已躍居全球第二大市場。然其抗體藥物產業才剛起步,2015及2016年的抗體藥物市場規模分別約78及104億元人民幣,隨著人口老齡化、人民經濟能力提升以及產業政策支持,預估2022年將達280~300億元人民幣,未來成長空間相當巨大。目前中國蛋白質/抗體藥物多是以生物仿製藥(Biosimilar) 為主,創新抗體藥將是一塊藍海,未來有很大的成長空間。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

提升台灣生技醫藥產業競爭力,聯亞集團培育莘莘學子不遺餘力

長庚大學生物科技產業博碩士學程於5月25日至聯合生物製藥蛋白質藥廠參訪及進行座談,活動內容除了介紹聯亞集團如何憑藉著遼闊的眼界及創新性思維,積極開創新局,來貫徹增進人類健康與生活品質的理想與使命外,也向學生說明新藥研發的流程與畢業後的就業出路;接著進行實驗室與產線參訪,最後由聯合生物製藥高階主管與長庚大學師生進行座談,使學生更加了解欲進入生技製藥產業界需具備的能力與心態。 繼續閱讀

發表於 公司新聞, 生醫新知, 社會經濟 | 發表迴響

United Neuroscience to Present at the Vatican’s Pontifical Council for Culture and the Cura Foundation’s Fourth International ‘Unite To Cure’ Conference in Vatican City

DUBLIN, April 27, 2018 /PRNewswire/ — United Neuroscience, Ltd., today announced that company co-founder Lou Reese will present at the Fourth International Conference, Unite to Cure: A Global Health Care Initiative, held April 26-28, 2018, at the Aula Nuova del Sinodo in Vatican City. The conference, organized by the Pontifical Council for Culture and the Cura Foundation, brings together journalists, advocates and thought leaders to discuss the impact of scientific innovation in medicine on culture and society. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息 | 發表迴響

美國UBI集團暨聯生藥與聯亞藥董事長王長怡博士 受邀在2018揚州生物醫藥論壇中專題演講

美國UBI集團暨聯生藥(6471)與聯亞藥(6562)董事長王長怡博士受邀於25日在揚州月畔灣酒店由揚州國家高新技術產業開發區舉辦的「2018揚州生物醫藥論壇」中給予專題演講。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United Neuroscience and University of Texas Southwestern Medical Center Announce Collaboration to Evaluate Endobody Vaccine Candidates Directed at Tau Protein for the Treatment and Prevention of Alzheimer’s Disease

Candidates Generated with United Neuroscience Endobody Technology Will be Tested at the Center for Alzheimer’s and Neurodegenerative Diseases 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United Neuroscience Signs Collaboration Agreement with French National Center for Scientific Research (CNRS) Laboratory to Target Protein Associated with Parkinson’s Disease

DUBLIN, March 22, 2018 /PRNewswire/ — United Neuroscience, Ltd., (UNS), today announced that it has entered a research collaboration agreement with the Ronald Melki laboratory at the French National Center for Scientific Research (CNRS) to investigate applications of the United Neuroscience Endobody technology platform in targeting pathogenic forms of alpha-synuclein protein. Under the agreement, United Neuroscience will contribute novel candidates targeting specific protein aggregates using the Endobody technology platform. Researchers in the CNRS laboratory will provide expertise in characterization of these candidates for key properties for their potential in generating therapeutics for Parkinson’s disease and other synucleinopathies. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

USC President, a US Congressman, a Nobel Laureate, United Neuroscience Executives and pioneering scientists are Amongst 2018 award recipients of Brain Mapping Foundation

LOS ANGELES, March 15, 2018 /PRNewswire-USNewswire/ — The Society for Brain Mapping and Therapeutics (SBMT) officially announced today they will hold their 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018. The event will include more than 400 scientists, engineers, physicians and surgeons where they will discuss pioneering technologies, policies and science advances in the fields including: multimodality imaging, nanoneurosurgery, nanobioelectronics, neurophotonics, cellular therapeutics (stem cell and neuro-immunotherapey), supercomputing, robotics (brain computer interface), neural transplantation and repair (double hand transplants), neuroengineering, Artificial Intelligence (AI), augmented reality and virtual reality in clinical neuroscience as well as computational and predictive modeling. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trial

United BioPharma (UBP, 6471) announced today that the company receives the approval from Thailand FDA an IND (Investigational New Drug) application for a multi-nation, multi-center, Phase III clinical trial with UB-421 monotherapy as HAART (Highly Active Anti-retroviral Therapy ) substitution in HIV infected patients. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥愛滋病抗體新藥UB-421多國多中心三期臨床試驗獲泰國FDA核准進行

聯生藥今日(6471)表示,其治療愛滋病單株抗體新藥UB-421規劃在台灣、中國與泰國三個地區執行之多國多中心HAART (Highly Active Anti-retroviral Therapy,抗反轉錄病毒療法) 取代性療法第三期臨床試驗,繼2017年11月7日獲得台灣衛福部食藥署 (TFDA) 核准後,今已於2018年3月14日獲得泰國食品藥品監督管理局(ThaiFDA)核發臨床藥物進口許可證(import license) ,核准三期UB-421臨床試驗之進行。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥與美國奇異公司再度攜手,將於揚州打造先進單株抗體藥物生產基地

聯生藥(6471) 今日表示,與美國奇異醫療集團生命科學部(GE Healthcare Life Sciences)再度攜手合作,將在揚州高新技術産業開發區打造世界先進的單株抗體藥物生產基地。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

UBP Construction Plan to start on new facility for biopharmaceutical manufacturing in China

United BioPharma (UBP, 6471) announced that construction will begin on a state-of-the-art biopharmaceutical manufacturing plant in China to support the development of key innovator, biobetter and biosimilar monoclonal antibody(mAb) drugs for the China market through its subsidiary, UBP (Yangzhou). 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥進軍中國 佈局抗體藥物市場

聯生藥(6471) 今日表示,將正式啟動中國抗體藥物建廠計畫。

聯生藥為拓展中國龐大且剛起步的單株抗體藥物市場,經兩年多的考察,於2017年4月與揚州高新技術産業開發區(以下簡稱「揚州高新區」)簽署合作協議,於揚州高新區建立蛋白質藥物生產基地,並接續於上海與揚州分別成立聯藥(上海)生物科技與聯生藥(揚州)生物醫藥兩家子公司,作為進軍中國醫藥市場之研發中心與抗體藥物生產基地。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響